← Leaderboards
Howard Feldman
University Of California, San Diego
$27,033,634
Attributed
$47,230,557
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $16.7M · FY2015–25$20M$15M$10M$5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$92,094,888 · 4
By mechanism
R01$47,230,557 · 3
U19$44,864,331 · 1
Top collaborators
- Gary E Gibson3 shared
- Jose A Luchsinger3 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Kaitlin B Casaletto$10,995,555
- Diane M. Jacobs$2,280,180
- Robert Scott Ross$18,254,836
- Liangfang Zhang$5,562,722
- Maurice S Swanson$17,857,475
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposSafetyS DiseaseProgramsClinical TrialsEffective TherapyPre-ClinicalLinkCognitionDementiaAffectDesignBasePharmacodynamicsNeuroimagingDisease ProgressionAmyloidPlacebosResourcesTrial DesignFundingSiteMild Cognitive ImpairmentEurope
Grant awards (23)
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$9,592,233
R01 · FY2025 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$11,038,947
R01 · FY2023 · AG
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease$2,494,955
R01 · FY2023 · AG · contact PI
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$9,664,204
R01 · FY2022 · AG
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease$3,726,446
R01 · FY2022 · AG · contact PI
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease$309,515
R01 · FY2022 · AG · contact PI
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease$4,343,433
R01 · FY2021 · AG · contact PI
Alzheimer's Disease Cooperative Study$8,741,293
U19 · FY2020 · AG · contact PI
Alzheimer's Disease Cooperative Study$8,803,397
U19 · FY2019 · AG · contact PI
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease$5,279,327
R01 · FY2019 · AG · contact PI
Alzheimer's Disease Cooperative Study$100,000
U19 · FY2018 · AG · contact PI
Alzheimer's Disease Cooperative Study$7,799,987
U19 · FY2017 · AG · contact PI
Alzheimer's Disease Cooperative Study$3,723,659
U19 · FY2017 · AG · contact PI
Alzheimer's Disease Cooperative Study$2,819,262
U19 · FY2017 · AG · contact PI
Alzheimer's Disease Cooperative Study$2,206,643
U19 · FY2017 · AG · contact PI
Alzheimer's Disease Cooperative Study$100,065
U19 · FY2017 · AG · contact PI
Alzheimer's Disease Cooperative Study$100,000
U19 · FY2017 · AG · contact PI
Alzheimer's Disease Cooperative Study$10,006,406
U19 · FY2016 · AG · contact PI
Alzheimer's Disease Cooperative Study$137,619
U19 · FY2016 · AG · contact PI
Alzheimer's Disease Cooperative Study$126,000
U19 · FY2016 · AG · contact PI
Alzheimer's Disease Cooperative Study$100,000
U19 · FY2016 · AG · contact PI
Alzheimer's Disease Cooperative Study$100,000
U19 · FY2016 · AG · contact PI
ACTIVE IMMUNOTHERAPY FOR COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME$781,497
R01 · FY2015 · AG · contact PI